Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1921P - Prognostic impact of [18F]FDG-PET/CT in differentiated thyroid cancer with bone metastasis: A French TUTHYREF study


17 Sep 2020


E-Poster Display


Arnaud Jannin


Annals of Oncology (2020) 31 (suppl_4): S1026-S1033. 10.1016/annonc/annonc293


A. Jannin1, L. Lamartina2, C. moutarde1, M. Djennaoui3, G. Lion4, M. vantyghem1, S. Leboulleux5, C. Do Cao6

Author affiliations

  • 1 Endocrinology, Centre Hospitalier Régional Universitaire de Lille, 59000 - Lille/FR
  • 2 Medecine Nuclear And Endocrine Oncology, Gustave Roussy, 94800 - villejuif/FR
  • 3 Department Of Public Health, Valenciennes Hospital, 59300 - Valenciennes/FR
  • 4 Nuclear Medicine, CHRU de Lille - Hôpital Claude Huriez, 59037 - Lille/FR
  • 5 Medecine Nuclear And Endocrine Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 6 Endocrinology, CHRU Lille- Hôpital Claude Huriez, 59037 - Lille/FR


Abstract 1921P


Bone metastases (BM) are frequent in differentiated thyroid cancer (DTC), affecting the skeleton at various extents, impacting negatively quality of life, being the leading cause of DTC-related morbidity and death. We aimed to evaluate (a) the overall survival (OS) and (b) assess predictive factors of radioiodine treatment (RAI) response in patients with DTC and BM.


178 consecutive DTC patients harboring BM were enrolled in this retrospective study conducted in two tertiary referral centres of the French national TUTHYREF network between 1989 and 2015. OS analysis was performed for the whole cohort while the 145 non-RAI refractory patients at BM diagnosis were evaluated for total RAI response (T-RAI-R) defined as the complete resolution of RAI uptake in the absence of morphologic progression of BM.


The median OS, calculated from BM diagnosis, was 57 months (24-93). The OS rate at 5 and 10 years from BM detection was 56.5% and 15.3% respectively for patients with BM RAI uptake but only 28.6 and 4.8% for patients without any significant radioiodine uptake. In multivariate analysis, OS was significantly reduced by T4 stage, BM FDG-PET/CT uptake and RAI refractory status (HR, 2.91; 95% CI, 1.27-6.65, p=0.113; HR, 3.79; 95% CI 1.23-11.71, p=0.0204; HR, 5.16; 95% CI 1.21- 21.93, p=0.0264, respectively). Among the 145 DTC non-RAI refractory patients at BM diagnosis, 46 patients (31.7%) achieved a T-RAI-R (32 patients with radioiodine alone and 14 with further local BM treatments). Patients without extra-skeletal metastasis and absence of BM FDG-PET/CT uptake were more likely to achieve T-RAI-R (OR, 0.11; 95% CI, 0.02-0.46, p=0.005; OR, 0.2; 95% CI, 0.04-0.80, p=0.0236, respectively).


Among DTC patients with newly diagnosed BM. BM FDG-PET/CT uptake is a prognostic factor for a T-RAI-R and for OS. FDG-PET/CT should be performed as soon as the BM diagnosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings